Abstract
The roles of autophagic cell death and apoptosis induced by topoisomerase inhibitor irinotecan in colon cancer cells with deleted p53 were investigated during 48 h. We report that irinotecan-dependent cytotoxicity and proapoptotic activity were reduced in the present model while autophagy levels significantly increased. Upon p53 transfection, cell demise rates increased, with cells bearing the features of apoptosis and autophagic cell death. The subsequent studies into mechanisms of cell death process revealed the important role of Bax in mediating mitochondrial and lysosomal leakage which might serve as leading signals for both apoptosis and autophagic cell death. These results suggest that different modes of cell death in p53 null colon cancer cells treated with cytostatics (irinotecan) may be activated simultaneously. Moreover, their interactions possibly occur at several stages and aren´t mutually exclusive. This might thus lead to a potential synergism with interesting therapeutic ramifications.
Keywords: Irinotecan, Colon cancer, Autophagy, p53, Chemotherapy, Autophagic cell death, Apoptosis, Bax, Lysosomes, Mitochondria.
Anti-Cancer Agents in Medicinal Chemistry
Title:The Role of Autophagic Cell Death and Apoptosis in Irinotecan-treated p53 Null Colon Cancer Cells
Volume: 13 Issue: 5
Author(s): Stanislav John, Jan Mls, Miroslav Cervinka and Emil Rudolf
Affiliation:
Keywords: Irinotecan, Colon cancer, Autophagy, p53, Chemotherapy, Autophagic cell death, Apoptosis, Bax, Lysosomes, Mitochondria.
Abstract: The roles of autophagic cell death and apoptosis induced by topoisomerase inhibitor irinotecan in colon cancer cells with deleted p53 were investigated during 48 h. We report that irinotecan-dependent cytotoxicity and proapoptotic activity were reduced in the present model while autophagy levels significantly increased. Upon p53 transfection, cell demise rates increased, with cells bearing the features of apoptosis and autophagic cell death. The subsequent studies into mechanisms of cell death process revealed the important role of Bax in mediating mitochondrial and lysosomal leakage which might serve as leading signals for both apoptosis and autophagic cell death. These results suggest that different modes of cell death in p53 null colon cancer cells treated with cytostatics (irinotecan) may be activated simultaneously. Moreover, their interactions possibly occur at several stages and aren´t mutually exclusive. This might thus lead to a potential synergism with interesting therapeutic ramifications.
Export Options
About this article
Cite this article as:
John Stanislav, Mls Jan, Cervinka Miroslav and Rudolf Emil, The Role of Autophagic Cell Death and Apoptosis in Irinotecan-treated p53 Null Colon Cancer Cells, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (5) . https://dx.doi.org/10.2174/1871520611313050015
DOI https://dx.doi.org/10.2174/1871520611313050015 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tissue Biomarkers for Prostate Cancer Radiation Therapy
Current Molecular Medicine Apoptosis-Inducing Effects of Amaryllidaceae Alkaloids
Current Medicinal Chemistry From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research
Current Pharmaceutical Biotechnology A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry Merging Traditional Chinese Medicine with Modern Drug Discovery Technologies to Find Novel Drugs and Functional Foods
Current Drug Discovery Technologies Non-Replicating Viral Vector-Based AIDS Vaccines: Interplay Between Viral Vectors and the Immune System
Current HIV Research BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
Current Cancer Drug Targets Lipoxygenase (LOX) Pathway: A Promising Target to Combat Cancer
Current Pharmaceutical Design Curcumin, an Active Constiuent of the Ancient Medicinal Herb Curcuma longa L.: Some Uses and the Establishment and Biological Basis of Medical Efficacy
CNS & Neurological Disorders - Drug Targets Novel Concepts in the Development of Platinum Antitumour Drugs: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Breast Cancer: A Review of Risk Factors and New Insights into Treatment
Current Cancer Therapy Reviews Molecular Targeted Therapies in the Management of Head and Neck Squamous Cell Carcinoma: Recent Developments and Perspectives
Anti-Cancer Agents in Medicinal Chemistry Photodynamic Therapy using Carbohydrate Conjugated Porphyrins
Drug Design Reviews - Online (Discontinued) VEGF Signal System: The Application of Antiangiogenesis
Current Medicinal Chemistry Statins and Alkylphospholipids as New Anticancer Agents Targeting Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry Dynamic Simulations of Pathways Downstream of ERBB-Family, Including Mutations and Treatments: Concordance with Experimental Results
Current Cancer Drug Targets Natural and Synthetic Iminosugars as Carbohydrate Processing Enzyme Inhibitors for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Patent Analysis as a Tool for Research Planning: Study on Natural Based Therapeutics Against Cancer Stem Cells
Recent Patents on Anti-Cancer Drug Discovery